SCHEMBL25544634

SCHEMBL25544634

OC[C@H](O)COc1cc(C2CCOCC2)c(-c2ccc(F)cc2)c2ccc(O)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
ESR1 P03372 6/20 0.33
MAPK14 Q16539 1/20 0.33
CYP1A2 P05177 3/20 0.32
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
S1PR1 P21453 1/20 0.32
PIK3CD O00329 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
AGTR1 P30556 1/20 0.31
LMNA P02545 1/20 0.31
PTGDR Q13258 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23896356 0.81 MAPK14 (0.35) ALDH2MAOAMAOBESR1MAPK14
SCHEMBL23896071 0.73 PRKAA2 (0.34) ESR1MAPK14KDM4EPIK3CDPIK3CA
SCHEMBL25545563 0.73 PRKAA2 (0.34) ESR1MAPK14KDM4EPIK3CDPIK3CA
SCHEMBL25544779 0.71 RPS6KA3 (0.40) ESR1MAPK14KDM4EPIK3CDPIK3CA
SCHEMBL23896303 0.70 PRKAA2 (0.36) ESR1KDM4EPIK3CDPIK3CALMNA
SCHEMBL23896358 0.70 ULK1 (0.36) ESR1MAPK14KDM4E
SCHEMBL23896127 0.67 GRM4 (0.41)
SCHEMBL23896369 0.67 RAF1 (0.39) PIK3CDPIK3CA
SCHEMBL25549283 0.66 ESR1 (0.36) ESR1KDM4EPIK3CDPIK3CAESR2
SCHEMBL25544052 0.66 GRM4 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 ALDH2 1669/4885MAOA 1913/4885MAOB 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.